1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. South & Central America Gastrointestinal Drugs Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. South & Central America Gastrointestinal Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. South & Central America Gastrointestinal Drugs Market Regional Analysis
6.2 South & Central America Gastrointestinal Drugs Market Revenue 2021-2031 (US$ Million)
6.3 South & Central America Gastrointestinal Drugs Market Forecast Analysis
7. South & Central America Gastrointestinal Drugs Market Analysis – by Drug Class
7.1 Biologics
- 7.1.1 Overview
- 7.1.2 Biologics: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Antidiarrheal and Laxatives
- 7.2.1 Overview
- 7.2.2 Antidiarrheal and Laxatives: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Acid Neutralizers
- 7.3.1 Overview
- 7.3.2 Acid Neutralizers: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Anti-inflammatory Drugs
- 7.4.1 Overview
- 7.4.2 Anti-inflammatory Drugs: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Antiemetic and Antinauseants
- 7.5.1 Overview
- 7.5.2 Antiemetic and Antinauseants: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. South & Central America Gastrointestinal Drugs Market Analysis – by Application
8.1 Irritable Bowel Syndrome
- 8.1.1 Overview
- 8.1.2 Irritable Bowel Syndrome: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Inflammatory Ulcerative Colitis
- 8.2.1 Overview
- 8.2.2 Inflammatory Ulcerative Colitis: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Crohn\'s Disease
- 8.3.1 Overview
- 8.3.2 Crohn\'s Disease: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Gastroenteritis
- 8.4.1 Overview
- 8.4.2 Gastroenteritis: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Celiac Disease
- 8.5.1 Overview
- 8.5.2 Celiac Disease: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. South & Central America Gastrointestinal Drugs Market Analysis – by Route Of Administration
9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Parenteral
- 9.2.1 Overview
- 9.2.2 Parenteral: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. South & Central America Gastrointestinal Drugs Market Analysis – by Distribution Channel
10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: South & Central America Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
11. South & Central America Gastrointestinal Drugs Market – South and Central America Analysis
11.1 Overview
11.2 South and Central America
- 11.2.1 South & Central America Gastrointestinal Drugs Market Breakdown, by Key
Country, 2024 and 2031 (%)
- 11.2.1.1 South & Central America Gastrointestinal Drugs Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 Brazil:
South & Central America Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.1.1 Brazil: South & Central America Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.1.2 Brazil: South & Central America Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.1.3 Brazil: South & Central America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.1.4 Brazil: South & Central America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
- 11.2.1.2 Argentina:
South & Central America Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.2.1 Argentina: South & Central America Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.2.2 Argentina: South & Central America Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.2.3 Argentina: South & Central America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.2.4 Argentina: South & Central America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
- 11.2.1.3 Rest of South and Central America:
South & Central America Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.3.1 Rest of South and Central America: South & Central America Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.3.2 Rest of South and Central America: South & Central America Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.3.3 Rest of South and Central America: South & Central America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.3.4 Rest of South and Central America: South & Central America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Sanofi SA
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 GSK Plc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Johnson & Johnson
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Bausch Health Companies Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 AstraZeneca Plc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 AbbVie Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Bayer AG
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Pfizer Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations